BRIEF published on 05/11/2026 at 09:05, 5 days 13 hours ago NuWays AG Recommends Buy for Aiforia Technologies Oyj NuWays AG Oncology Diagnostics Aiforia Technologies AI Pathology Healthcare M&A
PRESS RELEASE published on 05/11/2026 at 09:00, 5 days 13 hours ago Original-Research: Aiforia Technologies Oyj (von NuWays AG): BUY Update on Aiforia Technologies Oyj classification from NuWays AG including strong market catalyst and analysis on AI pathology in the clinical oncology diagnostics field NuWays AG Market Analysis Oncology Diagnostics Aiforia Technologies Oyj AI Pathology
BRIEF published on 04/17/2026 at 09:05, 29 days 13 hours ago Aiforia Technologies Secures Exclusive AI Partnership in France AI Diagnostics Aiforia Technologies PROSTIA Project AP-HP Partnership French Healthcare
PRESS RELEASE published on 04/17/2026 at 09:00, 29 days 13 hours ago Original-Research: Aiforia Technologies Oyj (von NuWays AG): BUY Aiforia Technologies Oyj selected as sole AI partner for PROSTIA project by Assistance Publique-Hôpitaux de Paris, expanding cancer diagnostics in France. Landmark deployment validates Aiforia's market leadership Cancer Diagnostics France AI Partner Aiforia Technologies Oyj PROSTIA Project
BRIEF published on 03/11/2026 at 09:05, 2 months 5 days ago Aiforia Technologies Oyj Sees Clinical Growth Surge European Market Cash Position Profitability Improvement Client Expansion Clinical Growth
PRESS RELEASE published on 03/11/2026 at 09:00, 2 months 5 days ago Original-Research: Aiforia Technologies Oyj (von NuWays AG): BUY Aiforia Technologies Oyj by NuWays AG analyzed: Clinical growth accelerates, profitability improves with increased share of wallet and workforce reductions. Target price EUR 3.8 Profitability NuWays AG Target Price Aiforia Technologies Oyj Clinical Growth
BRIEF published on 03/09/2026 at 09:05, 2 months 7 days ago Aiforia Technologies Oyj Poised for Growth in Clinical Segment Strategic Partnerships Revenue Expansion EBITDA Improvement Market Share Clinical Growth
PRESS RELEASE published on 03/09/2026 at 09:00, 2 months 7 days ago Original-Research: Aiforia Technologies Oyj (von NuWays AG): BUY Aiforia Technologies Oyj's clinical segment shows strong growth with a clear roadmap for scaling, leading to improved profitability and strategic partnerships. Research recommends buying with a target price of EUR 3.80 Strategic Partnerships Profitability Target Price Aiforia Technologies Oyj Clinical Growth
BRIEF published on 02/27/2026 at 09:05, 2 months 17 days ago Aiforia Technologies Oyj Anticipates Strong Clinical Revenue Growth Strategic Partnerships AI Technology Profitability Financial Growth Clinical Revenue
PRESS RELEASE published on 02/27/2026 at 09:00, 2 months 17 days ago Original-Research: Aiforia Technologies Oyj (von NuWays AG): BUY Aiforia Technologies Oyj's updated research report by NuWays AG reveals accelerated clinical revenue growth expectations, with key focus on AI technology adoption and strategic partnerships for sales growth NuWays AG Research Report Aiforia Technologies Oyj Clinical Revenue Growth AI Technology Adoption
Published on 05/16/2026 at 01:15, 21 hours 29 minutes ago Findev Inc. Announces a New Member of the Board of Directors
Published on 05/16/2026 at 00:00, 22 hours 44 minutes ago Onco-Innovations Strengthens Quality Testing for Lead PNKP Inhibitor Drug Candidate
Published on 05/15/2026 at 23:10, 23 hours 34 minutes ago Golden Minerals Reports First Quarter 2026 Financial Results
Published on 05/15/2026 at 23:00, 23 hours 44 minutes ago Jericho Energy Ventures Announces Transition to Semi-Annual Reporting to Enhance Efficiency
Published on 05/16/2026 at 16:08, 6 hours 35 minutes ago The publication of the audited financial statements for 2025 will be postponed to 12 June 2026 – management does not expect any significant changes to the figures already published
Published on 05/15/2026 at 20:10, 1 day 2 hours ago CPIPG Communication Concerning Voluntary Offer on NEXT RE Shares – Provisional Results Announcement
Published on 05/15/2026 at 18:10, 1 day 4 hours ago Virtual Science AI launches first AI-driven competitor activity tracking platform to support pharma asset launch success
Published on 05/15/2026 at 17:33, 1 day 5 hours ago Turkiye Garanti Bankasi A.S.: Regarding the Sale of Non-Performing Loans Portfolio
Published on 05/15/2026 at 15:08, 1 day 7 hours ago Notice of exercise of early redemption option of the subordinated note ISIN : FR0010203026
Published on 05/13/2026 at 17:45, 3 days 4 hours ago Infotel confirms its return to growth in Q1 2026 with revenue up 8.6%. Proposed dividend of €2 per share for 2025.
Published on 05/13/2026 at 17:45, 3 days 4 hours ago Disclosure of Share Capital and Voting Rights Outstanding as of April 30, 2026
Published on 05/13/2026 at 17:40, 3 days 5 hours ago Report on share repurchases from 6 to 12 May 2026
